Regulatory PathRegulatory requirements compared

Active substance

Lisdexamfetamine dimesilate

Open in the medicines table

SFDA Saudi Arabia — SFDA human drug list

Trade nameStrengthForm · routePackPublic priceTypeCompanyStatus
Vyvanse20 mgCapsule, hard · Oral use30 BottleSAR 317.65NCE · PrescriptionTakeda Pharmaceuticals International AGValid
Vyvanse30 mgCapsule, hard · Oral use30 BottleSAR 340.30NCE · PrescriptionTakeda Pharmaceuticals International AGValid
Vyvanse40 mgCapsule, hard · Oral use30 BottleSAR 363.00NCE · PrescriptionTakeda Pharmaceuticals International AGValid
Vyvanse50 mgCapsule, hard · Oral use30 BottleSAR 383.40NCE · PrescriptionTakeda Pharmaceuticals International AGValid
Vyvanse60 mgCapsule, hard · Oral use30 BottleSAR 399.30NCE · PrescriptionTakeda Pharmaceuticals International AGValid
Vyvanse70 mgCapsule, hard · Oral use30 BottleSAR 408.40NCE · PrescriptionTakeda Pharmaceuticals International AGValid
Indications — CHI Daman Drug Formulary

ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD); AUTISM SPECTRUM DISORDER

Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.